Oncogenesis· 2026Q1
Metabolic and epigenetic reprogramming as novel vulnerabilities in renal cell carcinoma
- 0citations
- Q1SCImago
- 2026year
Short summary
Renal cell carcinomas (RCCs) exhibit distinct metabolic and epigenetic vulnerabilities driven by genetic alterations, offering new therapeutic targets.
AI-generated from the title and abstract; the full text is not read.
Key points
- RCC subtypes (clear cell, papillary, chromophobe) display unique metabolic profiles and genetic drivers.
- VHL loss in clear cell RCC stabilizes HIF, enhancing energy production and metabolic reprogramming.
- Mutations in TCA cycle enzymes in papillary RCC lead to oncometabolite accumulation, causing pseudohypoxia and epigenetic dysregulation.
- Oncometabolites and mutations in epigenetic regulators create a feedback loop that fuels RCC progression.
- Therapeutic strategies could involve inhibiting oncometabolite accumulation, amino acid metabolism, lipid synthesis, or epigenetic enzymes.
AI-generated from the title and abstract; the full text is not read.
Abstract
Renal Cell Carcinomas (RCCs) are metabolically heterogeneous tumors with distinct genetic, epigenetic, and metabolic alterations. In clear cell Renal Cell Carcinoma, VHL gene loss leads to stabilization of Hypoxia Inducible Factors (HIF1α and HIF2α), promoting angiogenesis and metabolic reprogramming enhancing cellular energy production. Papillary Renal Cell Carcinoma, frequently harboring mutations in Tricarboxylic Acid cycle enzymes (FH, SDH), results in the accumulation of different “oncometabolites”, capable to drive pseudohypoxia and epigenetic dysregulation. Chromophobe Renal Cell Carcinoma is instead associated with mitochondrial defects and limited glycolytic activity. In this context, a tight interplay exists between metabolism and the epigenetic landscape. Oncometabolites are able to inhibit key chromatin-modifying enzymes, altering gene expression and promoting tumorigenesis. RCCs also exhibits frequent mutations in epigenetic regulators, further contributing to metabolic rewiring and tumor progression. Inhibiting oncometabolite accumulation, disrupting amino acid metabolism, modulating lipid anabolic routes, or targeting epigenetic enzymes could complement current treatments. Understanding the metabolic dependencies of RCC cells may lead to the development of novel, personalized therapies.
The authors' abstract, as published at the source. Oncogenesis, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Cancer ResearchBiochemistry, Genetics and Molecular Biology